Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun
Minjie
M
School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China. sun_minjie@163.com
Wang
Yu
Y
Shen
Jie
J
Xiao
Yanyu
Y
Su
Zhigui
Z
Ping
Qineng
Q
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D016466:CHO Cells; D045744:Cell Line, Tumor; D006224:Cricetinae; D003412:Cricetulus; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008081:Liposomes / Q000737:chemistry* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000188:drug therapy*; D015282:Octreotide / Q000737:chemistry* / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D017481:Receptors, Somatostatin / Q000378:metabolism*
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D010714:Phosphatidylethanolamines; D017481:Receptors, Somatostatin; C483858:phosphatidylethanolamine; D011092:Polyethylene Glycols; D004317:Doxorubicin; D015282:Octreotide